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HER-2 is considered a prognostic and predictive factor in early breast cancer, and it is fun-
damental for the decision about adjuvant systemic therapy. HER-2 is recognised as a strong
predictive factor for the efficacy of chemotherapy-containing anthracyclines even if there
are no prospective but only restrospective analysis from adjuvant chemotherapy trials
comparing anthracyclines-containing chemotherapy to CMF or similar regimens. More
contradictory is the role of HER-2 as predictive factor for the treatment with adjuvant che-
motherapy-containing antharcyclines and taxanes compared to only anthracyclines. In the
treatment of early breast cancer adjuvant trastuzumab reduces the risk of recurrence and
death if added to chemotherapy. Trastuzumab can be administered in different ways but
the concomitant administration with chemotherapy (taxanes), compared to sequential
administration, reduces the risk of recurrence significantly. At the same time the risk of
cardiotoxicity is increased using the concomitant instead of the sequential administration.
 2008 Elsevier Ltd. All rights reserved.1. Role of anthracyclines in HER-2 disease
Oxford metanalysis demonstrates that anthracyclines-based
chemotherapy compared to CMF and/or CMF-like regimens
significantly reduces the risk of recurrence and death of
11% (2p = 0.001) and 16% (2p < 0.00001), respectively, with a
corresponding absolute benefit of 3.4% and 4.2%, respec-
tively.1 Due to its own role of metanalysis, these results do
not take into account the wide variability of the studies, in
terms of different control arms, anthracyclines schedule
(sequential or not to CMF), cumulative anthracycline doses,
number of drugs associated to anthracyclines and number
of cycles administered. Then, data coming from metanalysis
should also be analysed considering the data coming from
randomised trials. The First step is to exclude the suboptimal
1–21 days intravenous (i.v.) schedule (i.e. cyclophosphamide
600 mg/m2, Methotrexate 40 mg/m2, 5-fluorouracil 600 mg/
m2 all administered i.v. at day 1 every 21 d), and to consider
only randomised trials in which the control arm is the clas-
sical CMF (i.e. cyclophosphamide 100 mg/m2 orally from dayer Ltd. All rights reserved
fax: +39 0456013411.
ore.it (M. Venturini).1 to 14, Methotrexate 40 mg/m2 i.v. days 1 and 8, 5-fluoroura-
cil 600 mg/m2 i.v. days 1 and 8 every 28 d) or the 1–8 i.v. sche-
dule (i.e. cyclophosphamide 600 mg/m2, Methotrexate 40 mg/
m2 and 5-fluorouracil 600 mg/m2 all administered i.v. at days
1 and 8 every 28 d). If these CMF-based regimens are com-
pared with sequential schedule (doxorubcin or epiruibcin
followed by CMF) or regimen with P6 cycles, with three
drugs and with doxorubicin 60 mg/m2 or epiruibcin 100 mg/
m2 per cycle, the reduction of death risk is higher with an
hazard ratio of HR = 0.80 (2p = 0.0004) in favour of anthracy-
clines.1 Recently, some authors argued that the role of
anthracycline in early breast cancer patients could be re-
stricted to HER2 positive disease. Gennari et al.2 conducted
a pooled analysis on 5354 patients, for whom HER-2 status
was available, enrolled in randomised trials comparing
anthracycline-based with non-anthracycline-based adjuvant
chemotherapy. In HER-2 positive disease, anthracyclines
demonstrated to be better both in terms of disease-free sur-
vival (HR = 0.71; 95% confidence interval (CI): 0.61–0.83,
p < 0.001) and overall survival (HR = 0.73; 95%CI: 0.62–0.85,
p < 0.001). On the contrary, in HER2 negative disease anthra-
cyclines seemed not to improve disease-free survival
(HR = 1.00; 95%CI: 0.90–1.11, p = 0.75) nor overall survival.
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it is important to underline the fact that the metanalysis
by Gennari et al. was a retrospective analysis and it may be
used only as ‘hypothesis generating’ to be prospectively
tested in randomised manner. Moreover, several anthracy-
clines schedules were suboptimal: ACx4, PAF, alternating
CMF/EV, EC or high dose EC, weekly epirubicin. Only CMF
followed by doxorubicin, FEC and CEF included in this met-
analysis can be considered optimal anthracyclines schedule.
Actually, only the results of a retrospective analysis from one
randomised trial, comparing an optimal regimen-containing
anthracyclines and optimal CMF, demonstrate that the
benefit of anthracyclines over CMF seems to be restricted
to HER-2 positive breast cancer. Retrospective data from
MA-5 study, comparing CEF (cyclophosphamide 100 mg/m2
orally from day 1 to day 14, epirubicin 60 mg/m2 i.v. days 1
and 8, 5-fluorouracil 600 mg/m2 i.v. days 1 and 8 every 28 d)
with oral CMF, demonstrate that risk reduction of recurrence
and death is 0.52 (p = 0.003) and 0.65 (p = 0.06), respectively, in
HER-2 positive disease, whilst is not statistically different is
HER-2 negative disease.3 Another study, BCIRG-006 trial,4
was designed to assess the role of adjuvant trastuzumab
added to chemotherapy-containing anthracyclines and
taxanes (four cycles doxorubicin and cyclophosphamide fol-
lowed by four cycles of docetaxel plus trastuzumab followed
by trastuzumab for a total of 1 year) and to chemotherapy
not containing anthracyclines (six cycles of Docetaxel, Car-
boplatin and trastuzumab followed by trastuzumab for a to-
tal of 1 year). After a median follow-up of 36 months (second
interim analysis), the addition of trastuzumab to anthracy-
clines and taxanes reduces the risk of recurrence and death
of 39% (p < 0.0001) and 41% (p = 0.004), respectively, as it re-
duces these risks of 33% (p = 0.0003) and 34% (p = 0.017),
respectively, if added to docetaxel and carboplatin, compared
to control arm AC followed by docetaxel. The difference
between the two schedules containing trastuzumab was
not statistically different neither in disease-free survival
(p = 0.42) nor in overall survival (p = 0.58). An investigational
analysis was conducted in patients with or without Topoiso-
merase-II co-amplification. Overall, 35% of patients had
Topoisomerase-II co-amplified with HER-2. The difference
in disease-free survival was not statistically significant be-
tween AC-TH and TCH in co-amplified or non co-amplified.
In conclusion, optimal anthracycline-based regimens are
better than optimal CMF regimens, and remain a gold stan-
dard treatment for all patients with early breast cancer,
who are candidates for chemotherapy. Further studies are
required to better select patients who may not benefit from
anthracyclines.2. Role of taxanes in HER-2 disease
Overall, taxanes added to anthracyclines as adjuvant chemo-
therapy for early breast cancer reduce the risk of recurrence
from 14% to 36% with an absolute benefit of 4–7%, depending
on trials, the use of paclitaxel or docetaxel and the sequen-
tial or concomitant schedules. Some studies (CALGB 9344,
PACS 01 and BCIRG 001) have also demonstrated an improve-
ment in overall survival of a relative 18–30% and an absolute3–6%.5–10 Different trials evaluated retrospectively the role of
adding taxanes to anthracyclines as adjuvant chemotherapy
in HER-2 positive disease. CALGB 934411 compared four cy-
cles of AC (doxorubicin and cyclophosphamide) with differ-
ent doses of doxorubicin (60 mg/m2, 75 mg/m2, 90 mg/m2)
to AC followed by four cycles of paclitaxel at 175 mg/m2
every 3 weeks. In HER-2 positive disease Paclitaxel was asso-
ciated with the reduction of recurrence and death risk of 41%
(p = 0.01) and 43% (p = 0.01), respectively, independently from
hormonal receptor status, whilst in HER-2 negative disease
the difference was significant only if hormonal receptors
were negative (p = 0.002). Another study, GEICAM 9906,
shows different result compared to CALGB 9344. GEICAM
990612 compared four cycles of FEC (fluorouracil 600 mg/m2,
epirubicin 90 mg/m2, cyclophosphamide 600 mg/m2 i.v.
administered every 21 d) followed by paclitaxel 100 mg/m2
for eight administrations to six cycles of FEC at the same
doses. In HER-2 positive breast cancer, disease-free survival
of FEC-P and FEC was 63% and 70%, respectively, even if
the difference was not statistically significant (HR = 1.18, CI
95%: 0.71–1.98, p = 0.52), whilst opposite results were found
with HER-2 negative breast cancer, with a statistically differ-
ent disease-free survival of 82% and 74%, respectively,
(HR = 0.65, CI 95%: 0.48–0.89, p = 0.0075). One possible expla-
nation of this result is the different cumulative dose of anth-
racyclines received in the FEC arm and FEC-P arms, which
was 540 mg/m2 and 360 mg/m2, respectively; this bias may
have contributed to find these results in HER-2 positive dis-
ease. However, similar results were found in Intergroup trial
E1199,13 in which patients receiving four cycles of AC were
then randomised to receive a different taxane with a differ-
ent schedule (control arm: paclitaxel 175 mg/m2 every 3
weeks, experimental arms: paclitaxel 80 mg/m2 weekly,
docetaxel 100 mg/m2 every 3e weeks, docetaxel 35 mg/m2
weekly). As compared to standard therapy (paclitaxel every
3 weeks), weekly paclitaxel was associated with a statisti-
cally significant improvement in disease-free survival
(HR = 1.27, CI 95%: 1.03–1.57, p = 0.006) and overall survival
(HR = 1.32, CI95%: 1.02–1.72, p = 0.01). Retrospective analysis
on HER-2 status showed a statistically significant improved
disease-free survival (HR1.33, CI 95%: 1.07–1.64, p = 0.009)
and overall survival (HR = 1.34, CI 95%: 1.02–1.76, p = 0.03) in
HER-2 negative disease but not in HER-2 positive disease nei-
ther in disease-free survival or overall survival. Differently
from GEICAM 9906, all patients receive the same cumulative
dose of doxorubicin (240 mg/m2). The role of HER2 for tax-
anes efficacy is not further supported by the results coming
from BCIRG-001,9 a trial which randomised node positive
breast cancer patients to receive six cycles of FAC (fluoroura-
cil 500 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide
500 mg/m2 i.v. every 21 d) or TAC (Docetaxel 75 mg/m2, doxo-
rubicin 50 m/m2, cyclophosphamide 500 mg/m2 i.v. every
21 d). TAC was associated with a statistically significant
improvement in disease-free survival independently from
HER-2 status event if the reduction was greater for HER-2 po-
sitive disease (HER-2 positive: HR = 0.60, CI 95%: 0.41–0.88;
HER-2 negative: HR = 0.76, CI 95%: 0.59–1.00). In conclusion,
available data do not support the use of HER2 to select the
choice to use or not to use a taxane in early breast cancer
patients.
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HER-2 disease
Adjuvant trastuzumab for early breast cancer has been stud-
ied associated with different schedules of adjuvant chemo-
therapy and this fact can have condition the results in
terms of efficacy. HERA trial randomised node positive breast
cancer, treated with P4 cycles of (neo)adjuvant chemother-
apy, followed by adjuvant radiotherapy (if needed), to no fur-
ther systemic therapy, 1 or 2 years of trastuzumab. After a
median follow-up of 1 and 2 years, adjuvant trastuzumab
was associated to an absolute improvement in terms of dis-
ease-free survival of 8.4% and 6.3%, respectively. From the
first to the second year, benefit in recurrences had a decrease
of a relative 25% and absolute 2%.14,15 From this point of view,
the result of the combined analysis of US trials (NSABP B-31
and NCCTG 9831) is different. After a median follow-up of
2.0 and 2.9 years the absolute benefit in terms of disease-free
survival is 11.7% and 12.8%, respectively, with a further
improvement of a relative 9% and an absolute 1%.16,17 The
benefit shown by US trials’, which remains over time, could
be a consequence of the type chemotherapy schedule associ-
ated with trastuzumab. In NSABP B-31 and NCCTG 9831 (with
the exclusion of sequential arm of N9831 that was not consid-
ered for the combined analysis) all patients were treated with
a sequential schedule of anthracyclines and taxanes (i.e. four
cycles of doxorubicin and cyclophosphamide, followed by 12
administrations of weekly Paclitaxel at 80 mg/m2 or four cy-
cles of 3-weekly Paclitaxel at 175 mg/m2). Trastuzumab was
administered concomitantly to Paclitaxel and then sequen-
tially for a total of 1 year and this type of administration
can produce a more definitive treatment. In fact, NCCTG
9831 compared 1 year of trastuzumab administered concom-
itant or sequential to Paclitaxel. The results, after a median
follow-up of 1.5 years, show that concomitant schedule is
associated with a significant improvement in terms of dis-
ease-free survival (HR = 0.64, 2p = 0.0114).18 This finding
seems to clarify the role of adjuvant trastuzumab adminis-
tered concomitantly to chemotherapy. Another important
consideration is the type of chemotherapy administered with
trastuzumab. In the HERA trial, the type of chemotherapy was
at physician discretion. Patients treated with anthracyclines
(68% of the population study) followed by trastuzumab, com-
pared to patients treated with only chemotherapy, received
an improvement in terms of disease-free survival of 43%, sta-
tistically significant (HR = 0.57, CI 95%: 0.46–0.71). Patients
treated with regimens containing anthracycline and taxanes
(26% of the population study) had a more little benefit and
were not statistically significant (HR = 0.80, CI 95%: 0.59–
1.10). Similar results were shown by NCCTG 9831 trial. This
trial randomised breast cancer patients to AC (doxorubicin
and cyclophosphamide) followed by weekly Paclitaxel or to
the same schedule with 1 year of trastuzumab administered
for 1 year. Trastuzumab was administered concomitantly
with weekly Paclitaxel and then for other 40 weeks or sequen-
tially to weekly Paclitaxel for 52 weeks. Trastuzumab added to
chemotherapy and administered with a concomitant sche-
dule was associated with a significant difference in disease-
free survival (HR = 0.64, CI 95%:0.46–0.91; p = 0.0114) comparedto trastuzumab administered sequentially. Interestingly,
trastuzumab was not associated with an improved disease-
free survival compared to control if administered with a
sequential schedule (HR = 0.87, CI 95%:0.67–1.13; p = 0.2936).
Similar results were shown by PACS-04,19 that is phase III
trial, randomizing early breast cancer patient to six cycles
of FEC (5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclo-
phosphamide 500 mg/m2 every 3 weeks) versus six cycles of
TE (Docetaxel 75 mg/m2 plus epirubicin 75 mg/m2 every 3
weeks). A second randomisation, after the results of trast-
uzumab in metastatic breast cancer was done: trastuzumab
was administered sequentially to chemotherapy for 1 year
and compared to observation. After a median follow-up of
48 months, adjuvant trastuzumab was associated with no sig-
nificant improvement in disease-free survival (HR = 0.86, CI
95%:0.61–1.22; p = 0.41). The possible conclusions of these re-
sults are two. The first: trastuzumab is not associated with a
better outcome if administered sequentially to chemotherapy
containing anthracyclines and taxanes. The second: only the
concomitant administration of trastuzumab and taxanes
(Paclitaxel) has been associated with benefit in disease-free
survival. Confirmatory data about the efficacy of concomitant
administration of chemotherapy and trastuzumab come from
the results of FINHER trial,20 a small trial, in which patients
were randomised to receive three cycles of Docetaxel or Vino-
relbine before three additional cycles of FEC (fluorouracil, epi-
rubicin and cyclophosphamide). A second randomisation was
done for cases HER-2 positive by FISH to receive or not trast-
uzumab for a total of 9 weeks administered concomitantly
with Docetaxel or Vinorelbine. After a median follow-up of
36 months, the administration of trastuzumab was associated
with an improvement of disease-free survival of 58% (p = 0.01)
and a trend for better overall survival (p = 0.07). The question
is how a short administration of trastuzumab could be protec-
tive in terms of reduction of the risk of recurrence. However
one of the possible keys of lecture is that the concomitant
administration seems to be a very effective treatment.
4. Cardiotoxicity of adjuvant trastuzumab
The first consideration about cardiotoxicity induced by trast-
uzumab is given by the analysis of NSABP B-3121,22 in which
patients received trastuzumab together with weekly Paclit-
axel after four cycles of AC (doxorubicin and cyclophospha-
mide). Patients could receive adjuvant trastuzumab after AC
if they were asymptomatic, with a left ventricular ejection
fraction (LVEF) upper to the normal limit and with a decline
from baseline (before AC) 615%. With these inclusion criteria
for receiving trastuzumab, 7.5% (149/1978) of patients, consid-
ering investigational and control arm, had one or more of
these criteria not satisfied and automatically excluded from
the treatment with trastuzumab. Between patients who re-
ceived adjuvant trastuzumab in NSABP B-31, 15.5% discontin-
ued treatment caused by asymptomatic or symptomatic
cardiac toxicity (1.9% in the first quarter, 6.3% in the second
quarter, 5.3% in the third quarter, 2.0% in the fourth quarter).
Globally, after a median of 3 years from day 1 of the fifth cycle
(the beginning of Paclitaxel), the incidence of cumulative car-
diac events (defined as the appearance of cardiac death or
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with trastuzumab and 0.9% in the control arm. Considering
the cardiotoxicity data after the completion of trastuzumab,
the respective incidences were 3.3% versus 0.5%. From these
data we can observe that cardiotoxicity seems to concentrate
during treatment with trastuzumab and the possibility to ob-
serve it after is low. In fact, after the year of treatment with
trastuzumab, only a further 0.5% and 0.4%, respectively, of
cardiac events occurred. Another cardiac safety analysis is
based on the results of NCCTG 983123 trial in which HER-2 po-
sitive breast cancer was treated with AC followed by either
weekly Paclitaxel alone or weekly Paclitaxel followed by trast-
uzumab for 1 year or weekly Paclitaxel administered concom-
itant with trastuzumab for 12 weeks followed by trastuzumab
alone for 40 weeks. In this trial we have the unique direct
comparison between sequential versus concomitant adminis-
tration of trastuzumab. Of the 2992 completing AC, with sim-
ilar results of NSABP B-31, 5.0% had LVEF decreasing
disallowing trastuzumab (decrease below normal limit: 2.4%,
decrease >15%: 2.6%). Between patients receiving trast-
uzumab, cumulative incidence of congestive heart failure or
cardiac death at 1 year after AC occurred in 0%, 1.6% and
3.3%, respectively, and after 3 years in 0.3%, 2.8% and 3.3%,
respectively. These results seem to be similar to the result
of NSABP B-31: congestive heart failure occurred early, with
most of the events before the end of adjuvant trastuzumab.
After trastuzumab the possibility of events decreased dramat-
ically. Interruption of trastuzumab because of symptomatic or
asymptomatic cardiac events was necessary in 18.8% (17.2%
asymptomatic and 1.6% symptomatic) of patients in the
sequential arm and in 28.9% (25.6% asymptomatic and 3.3%
symptomatic) of patients in the concomitant arm. Globally,
an absolute 10% of patients of difference between sequential
and concomitant administration of trastuzumab interrupted
it. Based on these data, considering another 5% of patients
who never received trastuzumab because of LVEF decrease
after AC, from 24% to 33% of patients could not receive the
planned treatment with trastuzumab without any interrup-
tions. Similar data are shown by NSABP B-31: in the concom-
itant arm until 23% of patients could not complete treatment
with trastuzumab without interruption. In the HERA trial24
patients receivedP4 four cycles in most cases of chemother-
apy-containing anthracyclines (94%) associated with taxanes
(26%). Trastuzumab was administered for 1 or 2 years sequen-
tially to chemotherapy (and radiotherapy if done) and com-
pared to control arm. No data are actually available for
patients who received 2 years of trastuzumab. One year of
trastuzumab was associatedwith a significant increase of car-
diac death or congestive heart failure (trastuzumab: 2.1%,
control: 0.2%), a similar data of 2.8% of the sequential arm
of NCCTG 9831. In HERA trial the proportion of patients who
interrupted trastuzumab because of cardiac disorders was
4.3%, a percentage that, compared to 18.8% of sequential
arm of NCCTG 9831, was lower. Another important consider-
ation is the analysis of cardiac safety of BCIRG-006,4 which
compared two regimens containing trastuzumab adminis-
tered for 1 year with or without anthracyclines. There were
no cases of cardiac death. There were 20 cases of CHF versus
4 in the anthracyclines arm and TCH arm, respectively, with a
statistically significant difference (p = 0.0015) and 18.0% ver-sus 8.6% relative declines of LVEF >10%, respectively
(p < 0.0001). Similar disease-free survival and overall survival
were registered with these two regimens, but with a less car-
diac toxicity with TCH. However, this schedule cannot be ap-
plied in patients with cardiac risk factors in order to reduce
cardiac toxicity because patients enrolled in this study were
free from cardiac problems.
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